Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Rubin

Showing results (1071-1080 of 1,202) with videos related to

Pageof 121
Sort By:
Chest|February 5, 2021
Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON StudySean Gaine, Olivier Sitbon, Richard N Channick, et al.
Cardiovascular Therapeutics|September 14, 2012
Rapid transition from inhaled iloprost to inhaled treprostinil in patients with pulmonary arterial hypertensionRobert C Bourge, Victor F Tapson, Zeenat Safdar, et al.
Gene Therapy|January 14, 2005
Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomasE Galanis, S H Okuno, A G Nascimento, et al.
Developmental Cell|September 26, 2017
CSNK1a1 Regulates PRMT1 to Maintain the Progenitor State in Self-Renewing Somatic TissueXiaomin Bao, Zurab Siprashvili, Brian J Zarnegar, et al.
European Journal of Heart Failure|November 22, 2021
The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON studyStephan Rosenkranz, Richard Channick, Kelly M Chin, et al.
Advances in Therapy|November 2, 2021
Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label ExtensionNazzareno Galiè, Sean Gaine, Richard Channick, et al.
Turk Kardiyoloji Dernegi Arsivi : Turk Kardiyoloji Derneginin Yayin Organidir|February 21, 2015
[Updated treatment algorithm of pulmonary arterial hypertension]Nazzareno Galiè, Paul A Corris, Adaani Frost, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|December 8, 2018
Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trialJean-Luc Vachiéry, Nazzareno Galiè, Joan Albert Barberá, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 12, 2014
Molecular profiling of Mycobacterium tuberculosis identifies tuberculosinyl nucleoside products of the virulence-associated enzyme Rv3378cEmilie Layre, Ho Jun Lee, David C Young, et al.
The Lancet. Microbe|January 26, 2026
Controlled human infection with Mycobacterium tuberculosis: practical considerations for clinical trialsChetan Seshadri, JoAnne L Flynn, Pauline Maiello, et al.
Pageof 121

Showing results (1071-1080 of 1,202) with videos related to

Sort By:
Pageof 121
Chest|February 5, 2021
Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON StudySean Gaine, Olivier Sitbon, Richard N Channick, et al.
Cardiovascular Therapeutics|September 14, 2012
Rapid transition from inhaled iloprost to inhaled treprostinil in patients with pulmonary arterial hypertensionRobert C Bourge, Victor F Tapson, Zeenat Safdar, et al.
Gene Therapy|January 14, 2005
Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomasE Galanis, S H Okuno, A G Nascimento, et al.
Developmental Cell|September 26, 2017
CSNK1a1 Regulates PRMT1 to Maintain the Progenitor State in Self-Renewing Somatic TissueXiaomin Bao, Zurab Siprashvili, Brian J Zarnegar, et al.
European Journal of Heart Failure|November 22, 2021
The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON studyStephan Rosenkranz, Richard Channick, Kelly M Chin, et al.
Advances in Therapy|November 2, 2021
Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label ExtensionNazzareno Galiè, Sean Gaine, Richard Channick, et al.
Turk Kardiyoloji Dernegi Arsivi : Turk Kardiyoloji Derneginin Yayin Organidir|February 21, 2015
[Updated treatment algorithm of pulmonary arterial hypertension]Nazzareno Galiè, Paul A Corris, Adaani Frost, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|December 8, 2018
Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trialJean-Luc Vachiéry, Nazzareno Galiè, Joan Albert Barberá, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 12, 2014
Molecular profiling of Mycobacterium tuberculosis identifies tuberculosinyl nucleoside products of the virulence-associated enzyme Rv3378cEmilie Layre, Ho Jun Lee, David C Young, et al.
The Lancet. Microbe|January 26, 2026
Controlled human infection with Mycobacterium tuberculosis: practical considerations for clinical trialsChetan Seshadri, JoAnne L Flynn, Pauline Maiello, et al.
Pageof 121